Aarti Pharmalabs (Mid Cap) Share Target 2025, 2026 To 2035
|
Aarti Pharmalabs Limited |
|||
|
Price: ₹662.05 (-2.58%) | ||
| 52 Week Low: ₹399.55 52 Week High: ₹721.70 |
|||
| Market Capital: 5,833.14 Crore (Midcap) | |||
| Healthcare -> Drug Manufacturers—Specialty & Generic | |||
Show Table of Contents
Table of Contents
- 1: Approach 1: Technical Analysis Paired With Price Action
- 1.1: Aarti Pharmalabs Share Price Target For 2025
- 1.1.1: Aarti Pharmalabs Share Price Target Table For 2025
- 1.1.2: Short-Term Technical Outlook
- 1.2: Aarti Pharmalabs Share Price Target For 2026
- 1.2.1: Aarti Pharmalabs Share Price Target Table For 2026
- 1.2.2: Long-Term Technical Outlook
- 2: Approach 2: Machine Learning By Studying Historical Prices
- 2.1: Aarti Pharmalabs Share Price Target Chart and Table From 2025, 2026, 2027 to 2035
- 3: Aarti Pharmalabs Brief Company Overview
- 4: Aarti Pharmalabs Financial Performance
- 4.0.1: Is Aarti Pharmalabs A Good Buy For Long Term?
Aarti Pharmalabs, a Mid Cap company in the Drug Manufacturers—Specialty & Generic Industry has delivered 24.2% returns in 1-year showing 4.1% quarterly revenue growth with 11.6% profit margin.
To predict the Aarti Pharmalabs's future market prices, we harnessed 2 dynamic approaches:
Approach 1: Technical Analysis Paired With Price Action
Approach 2: Machine Learning By Studying Historical Prices
Approach 1: Technical Analysis Paired With Price Action
Aarti Pharmalabs Share Price Target For 2025
The line chart displays the monthly closing prices of Aarti Pharmalabs with a black line. The green line shows three potential target prices for 2025, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Aarti Pharmalabs shares in 2025, see the table below.
Aarti Pharmalabs Share Price Target Table For 2025
| Level | Value | Analysis |
|---|---|---|
| 2025 Target 3 | 738.08 (+11.48%) | Fibonacci Extension Level 23.60% |
| 2025 Target 2 | 719.8 (+8.72%) | Price Action: Jan 2025 High |
| 2025 Target 1 | 711.35 (+7.44%) | Price Action: 30 Aug 2024 High |
| Current Price | 662.05 | Aarti Pharmalabs's share price as of 21 Jan 2025 |
| Stop Loss 1 | 640.0 (-3.34%) | Price Action: 01 Jul 2024 High |
| Stop Loss 2 | 632.95 (-4.4%) | Price Action: 18 Jul 2024 High |
| Stop Loss 3 | 626.45 (-5.38%) | Price Action: 04 Jul 2024 High |
Short-Term Technical Outlook
Current Technical Position: Aarti Pharmalabs is showing bullish momentum with price above both 25-day and 50-day moving averages.
Key Technical Level: The 25-day moving average at ₹644.84 serves as the nearest technical reference point.
Historical Returns: 3-month: +3.52% | 6-month: +4.69% | 1-year: +24.18%
Aarti Pharmalabs Share Price Target For 2026
The line chart displays the monthly closing prices of Aarti Pharmalabs with a black line. The green line shows three potential target prices for 2026, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Aarti Pharmalabs shares in 2026, see the table below.
Aarti Pharmalabs Share Price Target Table For 2026
| Level | Value | Analysis |
|---|---|---|
| 2026 Target 3 | 975.72 (+47.37%) | Price Action: Chart |
| 2026 Target 2 | 957.53 (+44.63%) | Price Action: Chart |
| 2026 Target 1 | 948.05 (+43.19%) | Fibonacci Extension Level 150.00% |
| Current Price | 662.05 | Aarti Pharmalabs's share price as of 21 Jan 2025 |
| Stop Loss 1 | 594.9 (-10.15%) | Price Action: 29 Jul 2024 Low |
| Stop Loss 2 | 588.8 (-11.07%) | Price Action: 25 Jul 2024 High |
| Stop Loss 3 | 582.5 (-12.02%) | Price Action: 20 Dec 2024 High |
Long-Term Technical Outlook
52-Week Range Analysis: Aarti Pharmalabs is currently trading near its 52-week high of ₹721.7, showing strong yearly momentum.
Long-Term Trend Analysis: The stock is maintaining a bullish long-term trend, trading above both 150-day and 250-day moving averages.
Long-Term Performance: 1-year: +24.18% | 3-year: NA | 5-year: NA
Stay ahead of the market! Get instant alerts on crucial market breakouts. Don't miss out on key opportunities!
Your phone number will be HIDDEN to other users.
Approach 2: Machine Learning By Studying Historical Prices
Aarti Pharmalabs Share Price Target Chart and Table From 2025, 2026, 2027 to 2035
| Year | Target 1 | Target 1 YoY Chg % | Target 2 |
|---|---|---|---|
| Current Price | ₹662.05 | ||
| 2025 | ₹1,119.28 | +69.06% | ₹1,136.07 |
| 2026 | ₹1,684.41 | +50.49% | ₹1,709.68 |
| 2027 | ₹2,468.49 | +46.54% | ₹2,505.52 |
| 2028 | ₹3,577.98 | +44.94% | ₹3,631.65 |
| 2029 | ₹4,704.47 | +31.48% | ₹4,775.04 |
| 2030 | ₹6,328.20 | +34.51% | ₹6,423.12 |
| 2031 | ₹9,148.70 | +44.57% | ₹9,285.93 |
| 2032 | ₹13,409.63 | +46.57% | ₹13,610.77 |
| 2033 | ₹15,875.72 | +18.39% | ₹16,113.86 |
| 2034 | ₹19,607.07 | +23.5% | ₹19,901.18 |
| 2035 | ₹24,104.14 | +22.93% | ₹24,465.70 |
Note: Target 1 and Target 2 represent price levels that the stock is most likely to achieve during the respective year, based on machine learning algorithms analyzing historical price patterns and market behavior. These predictions are generated through comprehensive analysis of the stock's historical data using advanced ML models.
Aarti Pharmalabs Brief Company Overview
Aarti Pharmalabs: A Global Leader in Pharmaceuticals Aarti Pharmalabs Limited is a leading manufacturer and supplier of active pharmaceutical ingredients (APIs) and pharmaceutical intermediates. The company's products are used in various therapeutic areas, including...
anti-hypertensive, anti-asthmatic, anti-cancer, central nervous system (CNS) agents, skincare, decongestant, cardiovascular, anti-thalassemic, analgesic, anti-diabetic, and ophthalmologic medications. Aarti Pharmalabs also develops new chemical entities (NCEs), regulatory starting materials (RSM), basic starting materials, key starting materials (KSM), key building blocks, xanthine derivatives, and allied products. The company provides contract development and manufacturing services for drug substance projects comprising NCEs, APIs, RSMs, and Intermediates for innovator pharmaceutical and biotech companies internationally. Established in 2019, Aarti Pharmalabs has a strong reputation in the industry for its commitment to quality and customer satisfaction. The company has a diverse product range and a global presence, serving customers in India and internationally.Aarti Pharmalabs Financial Performance
| Metric | Value | Description |
|---|---|---|
| Market Capital | 5,833.14 Crore | Market valuation of Aarti Pharmalabs's shares. |
| Revenue (TTM) | 1,967.98 Crore | Total revenue generated by Aarti Pharmalabs over the past twelve months. |
| Net Income (TTM) | +228.08 Crore | Net Profit or Loss after all the expenses over the past twelve months. |
| Operating Margin | +15.89% | Income from operations as a percentage of revenue, before taxes and interest. |
| Profit Margin | +11.59% | Net income as a percentage of revenue, after all expenses. |
| Revenue Growth (Quarterly) |
+4.09% | Change in revenue compared to the previous quarter. |
| Earnings Growth (YOY Quarterly) |
+5.4% | Change in earnings compared to the same quarter last year. |
| Debt-to-Equity (D/E) Ratio |
20.81 | Company's total debt divided by total shareholder equity. |
| Total Debt | 386.46 Crore | Sum of Aarti Pharmalabs's current & long-term financial obligations. |
| Total Cash | 99.51 Crore | Total amount of liquid funds available to Aarti Pharmalabs. |
Is Aarti Pharmalabs A Good Buy For Long Term?
Aarti Pharmalabs, a mid-cap stock with a market capitalization of ₹5,833.14 crore, shows mixed signals for long-term investment. While its Q2 2024-25 revenue (₹1,967.98 crore) and net profit (₹228.08 crore) are positive, representing an 11.59% profit margin and strong year-on-year growth (5.4%), the relatively high debt (₹386.46 crore) against a modest cash balance (₹99.51 crore) raises concerns. Past performance (69.75% return in the last 12 months) is impressive, but longer-term data (0.00% for 3 and 5 years) lacks context. Therefore, a cautious approach is advised; it's currently an average buy, warranting further due diligence before committing to a long-term position.
Disclaimer: The information provided on this page is for educational purposes only and should not be considered as financial advice. Historical performance data and technical analysis cannot guarantee future results. Stock investments are subject to market risks. Please consult with a qualified financial advisor before making any investment decisions.
All stock data shown is sourced from publicly available information and while we strive for accuracy, we cannot guarantee the absolute accuracy of all figures. Users should verify critical information from official sources before making investment decisions.
